Five-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma

Stereotactic ablative body radiotherapy (SABR) is a non-invasive treatment option for primary renal cell carcinoma (RCC). An individual patient data meta—analysis from the International Radiosurgery Consortium of the Kidney (IROCK) investigated long-term efficacy and safety of SABR for localized RCC. The analysis included data from 190 patients undergoing SABR at 12 institutions in five countries.The cumulative incidence of local failure at 5 years was 5.5% (95% CI 2.8-9.5). There were no grade 3 or 5 toxic effects; one patient developed an acute grade 4 duodenal ulcer and late grade 4 gastritis. The authors conclude that SABR is effective and safe in the long term for patients with primary RCC.